ArticleJournal of immunology (Baltimore, Md. : 1950)2014
CD8+ T cell-independent tumor regression induced by Fc-OX40L and therapeutic vaccination in a mouse model of glioma.
Article in Journal of immunology (Baltimore, Md. : 1950), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.Neuro-oncology · 2024Article
- TREM2 mediates MHCII-associated CD4bioRxiv : the preprint server for biology · 2023Article
- Article
- Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy.Journal of cancer research and clinical oncology · 2021Review
- Theoretical premises of a "three in one" therapeutic approach to treat immunogenic and nonimmunogenic cancers: a narrative review.Translational cancer research · 2021Review
- Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.Nature communications · 2018Article
- Contributions of immune cell populations in the maintenance, progression, and therapeutic modalities of glioma.AIMS allergy and immunology · 2018Article
- Elevated neutrophil-to-lymphocyte ratio is an independent poor prognostic factor in patients with intrahepatic cholangiocarcinoma.Oncotarget · 2016Article
- CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas.Cancers · 2016Review
- Association between interleukin 8-251 T/A and +781 C/T polymorphisms and glioma risk.Diagnostic pathology · 2015Article
- Glioblastoma exosomes and IGF-1R/AS-ODN are immunogenic stimuli in a translational research immunotherapy paradigm.Cancer immunology, immunotherapy : CII · 2015Article
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.Frontiers in oncology · 2015Review
- CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.Critical reviews in immunology · 2015Review
- Cracking the glioma-NK inhibitory code: toward successful innate immunotherapy.Oncoimmunology · 2014Article
- Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.Expert opinion on biological therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Despite the growing number of preclinical and clinical trials focused on immunotherapy for the treatment of malignant gliomas, the prognosis for this disease remains grim. Although some promising advances have been made, the immune response stimulated as a result of immunotherapeutic protocols has been inefficient at complete tumor elimination, primarily due to our lack of understanding of the necessary effector functions of the immune system. We previously demonstrated that a tumor lysate vaccine/Fc-OX40L therapy is capable of inducing enhanced survival and tumor elimination in the GL261 mouse glioma model. The following experiments were performed to determine the mechanism(s) of action of this therapy that elicits a potent antitumor immune response. The evidence subsequently outlined indicates a CD8(+) T cell-independent and CD4(+) T cell-, NK cell-, and B cell-dependent means of prolonged survival. CD8(+) T cell-independent tumor clearance is surprising considering the current focus of many cancer immunotherapy protocols. These results provide evidence for CD8(+) T cell-independent means of antitumor response and should lead to additional examination of the potential manipulation of this mechanism for future treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.